Skip Navigation



Carcinogenesis Advance Access published online on June 20, 2008
Carcinogenesis, doi:10.1093/carcin/bgn143
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/9/1799    most recent
bgn143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kotakadi, V. S.
Right arrow Articles by Hofseth, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotakadi, V. S.
Right arrow Articles by Hofseth, L. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis

Venkata S. Kotakadi1,**, Yu Jin1,**, Anne B. Hofseth1, Lei Ying1, Xiangli Cui1, Suresh Volate1, Alexander Chumanevich1, Patricia A. Wood2, Robert L. Price3, Anna McNeal3, Udai P. Singh3, Narendra P. Singh3, Mitzi Nagarkatt3, Prakash S. Nagarkatti3, Lydia E. Matesic4, Karine Auclair5, Michael J. Wargovich6 and Lorne J. Hofseth1,*

1 Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, SC 29208
2 WJB Dorn VA Medical Center and the School of Medicine, University of South Carolina, Columbia, SC 29209
3 Pathology and Microbiology, School of Medicine, University of South Carolina, Columbia, SC 29208
4 Department of Biological Sciences, University of South Carolina, Columbia, SC 29208
5 Department of Chemistry, McGill University, Montréal, Québec, Canada, H3A 2K6
6 Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, 29425

* To whom correspondence should be addressed: Lorne J. Hofseth, Ph.D., Department of Biomedical and Pharmaceutical Sciences, South Carolina College of Pharmacy, 770 Sumter St., Coker Life Sciences, Rm. 513C University of South Carolina, Columbia, SC 29208.Ph. 803-777-6627 (Office), 803-777-2080 (Lab), Fax: 803-777-8356. Email: hofseth{at}cop.sc.edu

Ulcerative colitis (UC) is a dynamic, chronic inflammatory condition of the colon associated with an increased colon cancer risk. Ginkgo biloba is a putative antioxidant, and has been used for thousands of years to treat a variety of ailments. The aim of this study was to test whether the standardized Ginkgo biloba extract, EGb 761, is an anti-oxidant that can be used to prevent and treat colitis in mice. Here we show that EGb 761 suppresses the activation of macrophages, and can be used to both prevent and treat mouse colitis. Markers of inflammation (iNOS, Cox-2, TNF-{alpha}) and inflammatory stress (p53 and p53-Phospho-Serine 15) are also down-regulated by EGb 761. Furthermore, we show that EGb 761 reduces the numbers of CD4+/CD25-/FoxP3- effector T cells in the colon. Interestingly, EGb 761 drives CD4+ effector T cell apoptosis in vitro, and in vivo, providing a mechanistic explanation to the reduction in numbers of this cell type in the colon. This current study is in agreement with previous studies supporting a use of EGb 761 as a complementary and alternative strategy to abate colitis and associated colon cancer.

Key Words: Inflammation • Ginkgo • EGb 761 • Colitis • Oxidative Stress

** These two authors contributed equal to the work presented in this paper.

Received March 10, 2008; revised May 14, 2008; accepted June 6, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.